ROQUEFORT THERAPEUTICS PLC

Share Issue/Capital Change • May 7, 2021

National Storage Mechanism | Additional information

RNS Number : 8158X

Roquefort Investments PLC

07 May 2021

7 May 2021

roquefort investments PLC

("Roquefort Investments" or the "Company")‎

Exercise of Warrants & Total Voting Rights

Roquefort Investments plc, an investment company established to acquire businesses focused on early stage opportunities in the medical biotechnology sector, ‎announces that it has received a notice to exercise warrants over a total of 1,500,000 Ordinary Shares (the "Warrant Shares"), for which funds of £15,000 have been received by the Company.

Application has been made for the admission of the Warrant Shares to trading on the Main Market of the London Stock Exchange, with such admission expected to become effective at 8.00 a.m. on 12th May 2021 ("Admission").

Following Admission, the total issued share capital of the Company will consist of 33,900,000 ordinary shares of one penny each. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Roquefort Investments plc
Stephen West (Chairman)	+44 (0)20 3290 9339
Optiva Securities Limited (Broker)
Christian Dennis	+44 (0)20 3411 1881

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

About Roquefort Investments

Roquefort Investments was formed as an investment company to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders.  It is envisaged that such acquisition or acquisitions will trigger a reverse takeover in accordance with the listing rules.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRDKABDBBKDKPK